Advances in Portopulmonary Hypertension

Slides:



Advertisements
Similar presentations
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Advertisements

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Exploring Early Combination Therapy in PAH
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Overview of GCA. Giant Cell Arteritis: Timely Diagnosis and Emerging Treatment Strategies.
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Progression After Cancer Immunotherapy in Advanced NSCLC
The Latest Data on Oral Prostacyclin Therapy in PAH
Protecting Patients With Varicose Veins
Epidemiology Venous Pathophysiology Etiology.
New Directions in iTTP.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
Advances in Dyslipidemia: What Have We Learned From ACC 2017
New Treatments for CTEPH
Addressing Iron Deficiency in Chronic HF
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Updates in Pulmonary Arterial Hypertension
Case Collection in RA: Highlights of an Interactive Workshop
Evolving Science of PAH Treatment
PCSK9 Inhibitors and Cardiovascular Outcomes
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Managing Depression is a Team Effort:
A Better Solution For Cancer Patients With VTE?
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
VTE in Cancer.
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Examining the Latest Evidence in PAH
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Extraordinary Cases of VTE Prevention in Patients With Cancer
How to Select Therapy In Newly Diagnosed CLL
Current and Emerging Data in CTEPH
Future Directions in Myelofibrosis: Implications of Emerging Approaches.
The Evolving Treatment Landscape in Atopic Dermatitis
Updates in Heart Failure:
Aspirin and Cardioprevention in 2018
Navigating Treatment Options in PAH
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
A Time for Change for Managing Patients With VTE Who Have Cancer
Implications of Emerging Treatments for Beta-Thalassemia
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Iron Deficiency in Heart Failure
Pulmonary Hypertension Updates From 2018
Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.
Elevated Admission Plasma Glucose Following ACS
Reducing Risk for CV Outcomes
DECLARE-TIMI 58.
CTEPH in Clinical Practice
Clinical Challenges and Updates in Managing Seizure Clusters
Saving the Day.
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Addressing Cardiovascular Events:
Incorporating New PAH Treatments Into Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Clinical Comparisons in CTEPH
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Pulmonary Arterial Hypertension and Hospitalizations
Merging the Art and Science of Managing nOH in Clinical Practice
Emerging Advances in Reducing Renal Complications of T2D
What's New in PAH?.
My PAH Patient.
Treatment Advances for RA
PCSK9 Inhibitors and Real-World Evidence
The Power of As-Treated Analyses
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Translating Data From Trial to Practice
Presentation transcript:

Advances in Portopulmonary Hypertension

PoPH

Defining PoPH

Hypothesis of PoPH Pathogenesis

TIPS Stent Placement

Epidemiology of PoPH

Survival and Prognostic Factors in PoPH

Multidisciplinary Approach in PoPH

Screening of PoPH

Additional Considerations in Diagnosing PoPH

PoPH Treatment Recommendations

Treatment of PoPH

Bosentan in PoPH (CP A and B)

PORTICO -- Macitentan in PoPH Study Design

PORTICO: Safety Considerations

PORTICO: Primary Endpoint

PORTICO: Secondary Endpoints*

PORTICO: Impact on Venous Pressure Gradient

Clinical Implications of PORTICO

Worsening of PoPH After LT

PORTICO Post Hoc Analysis: Improvement in Risk Categories Before LT

Treatment Algorithm for PoPH

Abbreviations

Abbreviations (cont)

Abbreviations (cont)